Greenphire Launches New Clinical Trial Budget Build and Negotiation Solution, EnvisiX

Integrated with the company’s industry-leading site payment technology, the new solution delivers efficiency and accuracy to support a streamlined and optimized study start-up

KING OF PRUSSIA, Pa. – June 2, 2020 – Greenphire, the global leader in financial lifecycle management for clinical trials, today announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution streamlines trial initiation for sponsors and CROs and eliminates guesswork during the budgeting process to deliver a smarter, more efficient workflow.

EnvisiX seamlessly integrates with eClinicalGPS, Greenphire’s industry-leading site payment solution, enabling unprecedented simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.

Read more.

Greenphire Launches Extension of its ConneX Solution, ConneX Patient Direct, as Trial Sites Seek Support in Response to COVID-19

New service allows clinical trial sites around the world to safely transport medications, equipment, and healthcare professionals to patients’ homes, ensuring needed patient support and enabling clinical trials to continue

KING OF PRUSSIA, Pa.April 8, 2020 /PRNewswire/ — Greenphire, the global leader in financial software for clinical trials, today announced the launch of its ConneX Patient Direct service to enable global clinical trial sites to continue their critical work and patient support in an effort to offset the impact of COVID-19. The new service, which is an extension of Greenphire’s ConneX concierge travel solution for clinical trials, provides “clean transport” for medications, equipment and healthcare professionals to visit patients in their homes, enabling patients to receive much-needed medications and monitoring, and sites and sponsors to continue their trials without disruption.

New FDA and EMA Guidelines for the conduct of clinical trials during COVID-19 pave the way for sponsors to evaluate whether alternative methods for safety assessments could be implemented when necessary and feasible, and would be sufficient to assure the safety of trial participants.

Read more.